• Research and Development

  LOXL2 Inhibitor Shows Promise in Phase 1 Pulmonary Fibrosis Trial

  Posted by Community Member on October 23, 2018 at 2:12 pm

  Pharmaxis’ first small molecule inhibitor of LOXL2 was found safe and well tolerated in a Phase 1 trial in healthy volunteers. Click here to learn more.

  What do you think about this news?

  replied 1 Member · 0 Replies
• 0 Replies

Log In to Reply